Navigation Links
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Date:10/28/2008

d/or a positive ECL were used to identify an active infection that required therapeutic intervention, and animals were then treated with either Valortim or saline (control).

In this study, 94 percent (30/32) of the animals were subsequently shown to be bacteremic at the time of treatment. Twelve of the NZW rabbits were treated with an intravenous (IV) 10 mg/kg dose of Valortim, 8 were treated with a 20 mg/kg IV dose of Valortim, and 12 were treated with IV saline in the control group. Study findings showed that 100 percent (8/8) of the 20 mg/kg Valortim-treated animals survived compared to 83 percent (10/12) in the 10 mg/kg Valortim-treated group and 8 percent (1/12) in the control group.

About Valortim

Valortim (MDX-1303) is a fully human monoclonal antibody designed to protect against and treat anthrax infection, including inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium. The investigational antibody is designed to target a protein component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is believed to initiate the onset of the illness by attaching to cells in the infected person, and then is believed to facilitate the entry of additional destructive toxins into the cells. Valortim is designed to target anthrax protective antigen and protect the cells from damage by the anthrax toxins.

As previously presented, Valortim has been administered intravenously and intramuscularly to healthy human volunteers in a completed Phase 1 study, was well tolerated at doses as high as 20 mg/kg (IV), and was not immunogenic. Pharmacokinetic analysis suggested that doses as low as 1 mg/kg resulted in circulating levels of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been vaccinated with anthrax vaccine.

Preclinical
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
(Date:8/19/2014)... 2014   Synthetic Biologics, Inc. (NYSE ... biologic and drug programs targeting specific pathogens that ... its novel C. difficile development program ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), ... Synthetic Biologics, Senior Vice President, ...
(Date:8/19/2014)... AZ (PRWEB) August 19, 2014 Sales ... launch of its online sales skills training course ... sales skills. , MedTech clinical staff spend the majority ... a hospital, standalone medical center, or physician practice – ... staff. But why stop there? Sales Horizons believes clinical ...
(Date:8/18/2014)... -- A new therapy developed by researchers at ... of Medicine and Columbia University Medical Center (CUMC) ... cardiovascular disease treatment. , The researchers demonstrated ... therapy could selectively inhibit blood vessel re-narrowing and ... using a balloon catheter to open narrowed or ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... 16 NanoSmart™ Pharmaceuticals, Inc., a California corporation developing ... received a Notice of Allowance for a US patent ... "We have taken an approach to targeting tumors that ... CEO of the company. "While most of cancer research ...
... Announces Record Second Quarter 2010 Results -- HARBIN, China, Aug. 16 /PRNewswire-Asia/ -- ... ... --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... Aug. 16 NeoStem, Inc. (NYSE Amex: ... company with product and service revenues, global research and ... U.S. adult stem cells, China adult stem cells, and ... quarter 2010. Second Quarter Results ...
Cached Biology Technology:NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 2Nutrastar International Inc. Announces Record Second Quarter 2010 Results 3Nutrastar International Inc. Announces Record Second Quarter 2010 Results 4Nutrastar International Inc. Announces Record Second Quarter 2010 Results 5Nutrastar International Inc. Announces Record Second Quarter 2010 Results 6Nutrastar International Inc. Announces Record Second Quarter 2010 Results 7Nutrastar International Inc. Announces Record Second Quarter 2010 Results 8Nutrastar International Inc. Announces Record Second Quarter 2010 Results 9Nutrastar International Inc. Announces Record Second Quarter 2010 Results 10NeoStem Provides Second Quarter Update 2NeoStem Provides Second Quarter Update 3NeoStem Provides Second Quarter Update 4
(Date:8/20/2014)... In leaves, photosystem 1 (PS1) absorbs light and ... of carbon dioxide to biomass. Photovoltaic devices, mostly ... light but produce electricity. One approach for the ... replacing the semi-conductor with the isolated membrane protein ... isolates a highly stable PS1 from thermophilic cyanobacteria ...
(Date:8/20/2014)... Aug. 20, 2014  The second annual Biometrics ... Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and ... The theme of this year,s event is Mobility ... "Biometrics UnPlugged: Mobility at the Crossroads ...
(Date:8/19/2014)... students, chances of completing introductory biology courses and ... implemented a comprehensive student success program, employing various ... , Through a grant from the Texas Higher ... and Biochemistry embarked on a pilot program focusing ... and "Introductory Biology" for science majors. These two ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... The Press Room will be on the fifth floor of ... the Main Lecture Room, offering free wireless access, the book ... January 6 through Friday, January 8, 7:30 a.m.-5:00 p.m., and ... press is free. Two events are open to the ...
... glioma, the most common primary brain tumor, new findings ... cancer. A UCSF-led team of scientists has identified ... stem cells underly a type of glioma called oligodendroglioma. ... to therapy than other brain tumors such as glioblastoma ...
... the allergic reactions that asthmatics suffer towards a common ... had the mould growing in their own lungs. ... Glenfield Hospital has been published in the December 2010 ... Critical Care Medicine . The team based in ...
Cached Biology News:Joint Mathematics Meetings in New Orleans Jan. 6-9 2Joint Mathematics Meetings in New Orleans Jan. 6-9 3Joint Mathematics Meetings in New Orleans Jan. 6-9 4Joint Mathematics Meetings in New Orleans Jan. 6-9 5Joint Mathematics Meetings in New Orleans Jan. 6-9 6Joint Mathematics Meetings in New Orleans Jan. 6-9 7Cell of origin for brain tumors may predict response to therapy 2Cell of origin for brain tumors may predict response to therapy 3New asthma research breaks the mold 2
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
AC input: 50-60 Hz230 V...
... arraying proteins of interest with sensitive ... DiscoverLight Protein Array Kits allow for ... lysate or antibody in a low-density ... designed nitrocellulose membranes with a 384-grid ...
Biology Products: